ArticleInternational journal of cardiology2021
Identification of a novel presumed cardiac sarcoidosis category for patients at high risk of disease.
Article in International journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.Frontiers in medicine · 2022Pooled it
- Implications of the 2024 American Heart Association Classification of Cardiac Sarcoidosis: Characteristics and Outcome of Patients Across the Continuum of Diagnostic Likelihood.Journal of the American Heart Association · 2026Article
- Diagnostic Approach to Left Ventricular Hypertrophy: A Review.US cardiology · 2026Review
- Imaging Pitfalls in the Detection of Infiltrative Cardiomyopathies.JACC. Case reports · 2025Article
- Endomyocardial biopsy in the diagnosis of cardiac sarcoidosis.European journal of heart failure · 2025Article
- Pharmacist Medication Titration Program for Patients With Cardiac Sarcoidosis and Systolic Heart Failure: A Retrospective Cohort Study.Journal of the American Heart Association · 2024Article
- A framework for exclusion of alternative diagnoses in sarcoidosis.Journal of autoimmunity · 2024Review
- A fearsome evolution of presumed cardiac sarcoidosis: The sarcoid-lymphoma syndrome.International journal of cardiology. Heart & vasculature · 2024Article
- Can FDG-PET Imaging Identify Cardiac Sarcoidosis Disease Phenotypes?Current cardiology reports · 2024Review
- 30-Year Trends in the Incidence, Characteristics, and Outcome of Cardiac Sarcoidosis in a Nationwide Cohort.JACC. Advances · 2024Article
- Cardiac Sarcoidosis-Diagnostic and Therapeutic Challenges.Journal of clinical medicine · 2024Review
- Clinical Response to Tumor Necrosis Factor-α Inhibitor Therapy in the Management of Cardiac Sarcoidosis.The American journal of cardiology · 2023Article
- Long-Term Outcomes of Cardiac Sarcoid: Prognostic Implications of Isolated Cardiac Involvement and Impact of Diagnostic Delays.Journal of the American Heart Association · 2023Observational
- Real-Life Utilization of Criteria Guidelines for Diagnosis of Cardiac Sarcoidosis (CS).Journal of clinical medicine · 2023Article
- Prognostic Implications of Sarcoidosis Granulomas - Insights From the Multicenter Registry, the Japanese Cardiac Sarcoidosis Prognostic Study.Circulation reports · 2023Article
- Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis.European heart journal · 2023Article
- The Mechanism and Natural History of Mitral Regurgitation in Cardiac Sarcoidosis.The American journal of cardiology · 2023Article
- Clinical features and prognosis of isolated cardiac sarcoidosis diagnosed using new guidelines with dedicated FDG PET/CT.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Article
- Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.Journal of cardiac failure · 2022Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundHistologic evidence is required for a definitive diagnosis of cardiac sarcoidosis (CS) by published guidelines; however, the sporadic nature of the disease may produce false negative biopsy results, causing CS to be underdiagnosed. We sought to establish a clinical category of CS absent histologic findings.
methodsPatients evaluated for CS were stratified into 3 groups: probable CS and definite CS based on Heart Rhythm Society (HRS) criteria and presumed CS, ie, patients without any histologic evidence of sarcoidosis, but with unexplained high-grade atrioventricular block or ventricular arrhythmia and findings suggestive of CS on either cardiac magnetic resonance imaging or positron emission tomography. The primary end point was hospitalization-free and overall survival at 10 years.
resultsA total of 383 patients were included in the study: 59, definite CS; 223, probable CS; and 101, presumed CS (62, isolated CS and 39, systemic CS). Compared with patients meeting HRS criteria for CS, patients with presumed CS had lower odds of New York Heart Association class III or IV symptoms (odds ratio [OR], 0.44 [95% CI, 0.23-0.83]; P = .01) but greater odds of previous ventricular tachycardia (OR, 2.4 [95% CI, 1.4-4.0]; P = .001) or history of resuscitated sudden cardiac arrest (OR, 2.9 [95% CI, 1.0-8.6]; P = .05). Hospitalization-free and overall survival were similar among groups (P = .51 and P = .71, respectively).
conclusionsClinical categorization of patients with presumed CS identified a high-risk cohort comparable to patients with histologic evidence of disease, although caution should be exercised in reaching this diagnosis without paying due diligence to the differential diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.